KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (“GammaCan” or “the Company”) (OTCBB: GCAN), a developer of novel immunotherapies to treat cancer, announced today the completion of a $6.5 million private placement with a group of investors lead by T.R. Winston & Company, LLC. The Company issued 16,250,000 common shares at a price of $0.40 per share, and warrants equal to the amount of shares issued, exercisable at $0.48. Details of the transaction will be described in a Form 8-K to be filed with the Securities and Exchange Commission.
